#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-15	Transdiagnostic	_
1-2	16-23	Effects	_
1-3	24-26	of	_
1-4	27-39	Ventromedial	_
1-5	40-50	Prefrontal	_
1-6	51-57	Cortex	_
1-7	58-70	Transcranial	_
1-8	71-79	Magnetic	_
1-9	80-91	Stimulation	_
1-10	92-94	on	_
1-11	95-98	Cue	_
1-12	99-109	Reactivity	_
1-13	110-120	BACKGROUND	_
1-14	121-122	:	_
1-15	123-131	Elevated	_
1-16	132-139	frontal	_
1-17	140-143	and	_
1-18	144-152	striatal	_
1-19	153-163	reactivity	_
1-20	164-166	to	_
1-21	167-171	drug	_
1-22	172-176	cues	_
1-23	177-179	is	_
1-24	180-181	a	_
1-25	182-197	transdiagnostic	_
1-26	198-206	hallmark	_
1-27	207-209	of	_
1-28	210-219	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-29	220-223	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-30	224-233	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-31	234-235	.	_

2-1	236-239	The	_
2-2	240-244	goal	_
2-3	245-247	of	_
2-4	248-253	these	_
2-5	254-265	experiments	_
2-6	266-269	was	_
2-7	270-272	to	_
2-8	273-282	determine	_
2-9	283-285	if	_
2-10	286-288	it	_
2-11	289-291	is	_
2-12	292-300	possible	_
2-13	301-303	to	_
2-14	304-312	decrease	_
2-15	313-320	frontal	_
2-16	321-324	and	_
2-17	325-333	striatal	_
2-18	334-344	reactivity	_
2-19	345-347	to	_
2-20	348-352	drug	_
2-21	353-357	cues	_
2-22	358-360	in	_
2-23	361-365	both	_
2-24	366-373	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
2-25	374-379	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
2-26	380-383	and	_
2-27	384-389	heavy	_
2-28	390-397	alcohol	_
2-29	398-403	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
2-30	404-411	through	_
2-31	412-422	continuous	_
2-32	423-428	theta	_
2-33	429-434	burst	_
2-34	435-446	stimulation	_
2-35	447-448	(	_
2-36	449-453	cTBS	_
2-37	454-455	)	_
2-38	456-458	to	_
2-39	459-462	the	_
2-40	463-467	left	_
2-41	468-480	ventromedial	_
2-42	481-491	prefrontal	_
2-43	492-498	cortex	_
2-44	499-500	(	_
2-45	501-506	VMPFC	_
2-46	507-508	)	_
2-47	509-510	.	_

3-1	511-518	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
3-2	519-520	:	_
3-3	521-524	Two	_
3-4	525-539	single-blinded	_
3-5	540-541	,	_
3-6	542-556	within-subject	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
3-7	557-558	,	_
3-8	559-565	active	http://maven.renci.org/NeuroBridge/neurobridge#Activity
3-9	566-581	sham–controlled	http://maven.renci.org/NeuroBridge/neurobridge#Activity
3-10	582-593	experiments	_
3-11	594-598	were	_
3-12	599-608	performed	_
3-13	609-616	wherein	_
3-14	617-623	neural	_
3-15	624-634	reactivity	_
3-16	635-637	to	_
3-17	638-650	drug/alcohol	_
3-18	651-655	cues	_
3-19	656-662	versus	_
3-20	663-670	neutral	_
3-21	671-675	cues	_
3-22	676-679	was	_
3-23	680-689	evaluated	_
3-24	690-701	immediately	_
3-25	702-708	before	_
3-26	709-712	and	_
3-27	713-718	after	_
3-28	719-728	receiving	_
3-29	729-733	real	_
3-30	734-736	or	_
3-31	737-741	sham	_
3-32	742-746	cTBS	_
3-33	747-748	(	_
3-34	749-752	110	_
3-35	753-754	%	_
3-36	755-762	resting	_
3-37	763-768	motor	_
3-38	769-778	threshold	_
3-39	779-780	,	_
3-40	781-785	3600	_
3-41	786-792	pulses	_
3-42	793-794	,	_
3-43	795-798	Fp1	_
3-44	799-807	location	_
3-45	808-809	;	_
3-46	810-812	N=	_
3-47	813-815	49	_
3-48	816-817	:	_
3-49	818-820	25	_
3-50	821-828	cocaine	_
3-51	829-834	users	_
3-52	835-836	[	_
3-53	837-847	experiment	_
3-54	848-849	1	_
3-55	850-851	]	_
3-56	852-853	,	_
3-57	854-856	24	_
3-58	857-864	alcohol	_
3-59	865-870	users	_
3-60	871-872	[	_
3-61	873-883	experiment	_
3-62	884-885	2	_
3-63	886-887	]	_
3-64	888-889	;	_
3-65	890-893	196	_
3-66	894-899	total	_
3-67	900-910	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-68	911-919	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-69	920-929	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-70	930-937	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-71	938-943	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-72	944-945	)	_
3-73	946-947	.	_

4-1	948-959	Generalized	_
4-2	960-979	psychophysiological	_
4-3	980-991	interaction	_
4-4	992-995	and	_
4-5	996-1005	three-way	_
4-6	1006-1023	repeated-measures	_
4-7	1024-1032	analysis	_
4-8	1033-1035	of	_
4-9	1036-1044	variance	_
4-10	1045-1049	were	_
4-11	1050-1054	used	_
4-12	1055-1057	to	_
4-13	1058-1066	evaluate	_
4-14	1067-1079	cTBS-induced	_
4-15	1080-1087	changes	_
4-16	1088-1090	in	_
4-17	1091-1095	drug	_
4-18	1096-1110	cue-associated	_
4-19	1111-1121	functional	_
4-20	1122-1134	connectivity	_
4-21	1135-1142	between	_
4-22	1143-1146	the	_
4-23	1147-1151	left	_
4-24	1152-1157	VMPFC	_
4-25	1158-1161	and	_
4-26	1162-1167	eight	_
4-27	1168-1175	regions	_
4-28	1176-1178	of	_
4-29	1179-1187	interest	_
4-30	1188-1189	:	_
4-31	1190-1197	ventral	_
4-32	1198-1206	striatum	_
4-33	1207-1208	,	_
4-34	1209-1213	left	_
4-35	1214-1217	and	_
4-36	1218-1223	right	_
4-37	1224-1231	caudate	_
4-38	1232-1233	,	_
4-39	1234-1238	left	_
4-40	1239-1242	and	_
4-41	1243-1248	right	_
4-42	1249-1256	putamen	_
4-43	1257-1258	,	_
4-44	1259-1263	left	_
4-45	1264-1267	and	_
4-46	1268-1273	right	_
4-47	1274-1280	insula	_
4-48	1281-1282	,	_
4-49	1283-1286	and	_
4-50	1287-1295	anterior	_
4-51	1296-1305	cingulate	_
4-52	1306-1312	cortex	_
4-53	1313-1314	.	_

5-1	1315-1322	RESULTS	_
5-2	1323-1324	:	_
5-3	1325-1327	In	_
5-4	1328-1332	both	_
5-5	1333-1344	experiments	_
5-6	1345-1346	,	_
5-7	1347-1352	there	_
5-8	1353-1356	was	_
5-9	1357-1358	a	_
5-10	1359-1370	significant	_
5-11	1371-1382	interaction	_
5-12	1383-1390	between	_
5-13	1391-1400	treatment	_
5-14	1401-1402	(	_
5-15	1403-1412	real/sham	_
5-16	1413-1414	)	_
5-17	1415-1418	and	_
5-18	1419-1423	time	_
5-19	1424-1425	(	_
5-20	1426-1434	pre/post	_
5-21	1435-1436	)	_
5-22	1437-1438	.	_

6-1	1439-1441	In	_
6-2	1442-1446	both	_
6-3	1447-1458	experiments	_
6-4	1459-1460	,	_
6-5	1461-1472	cue-related	_
6-6	1473-1483	functional	_
6-7	1484-1496	connectivity	_
6-8	1497-1500	was	_
6-9	1501-1514	significantly	_
6-10	1515-1525	attenuated	_
6-11	1526-1535	following	_
6-12	1536-1540	real	_
6-13	1541-1545	cTBS	_
6-14	1546-1552	versus	_
6-15	1553-1557	sham	_
6-16	1558-1562	cTBS	_
6-17	1563-1564	.	_

7-1	1565-1570	There	_
7-2	1571-1574	was	_
7-3	1575-1577	no	_
7-4	1578-1589	significant	_
7-5	1590-1601	interaction	_
7-6	1602-1606	with	_
7-7	1607-1613	region	_
7-8	1614-1616	of	_
7-9	1617-1625	interest	_
7-10	1626-1629	for	_
7-11	1630-1636	either	_
7-12	1637-1647	experiment	_
7-13	1648-1649	.	_

8-1	1650-1661	CONCLUSIONS	_
8-2	1662-1663	:	_
8-3	1664-1668	This	_
8-4	1669-1671	is	_
8-5	1672-1675	the	_
8-6	1676-1681	first	_
8-7	1682-1697	sham-controlled	_
8-8	1698-1711	investigation	_
8-9	1712-1714	to	_
8-10	1715-1726	demonstrate	_
8-11	1727-1728	,	_
8-12	1729-1731	in	_
8-13	1732-1735	two	_
8-14	1736-1747	populations	_
8-15	1748-1749	,	_
8-16	1750-1754	that	_
8-17	1755-1760	VMPFC	_
8-18	1761-1765	cTBS	_
8-19	1766-1769	can	_
8-20	1770-1779	attenuate	_
8-21	1780-1786	neural	_
8-22	1787-1797	reactivity	_
8-23	1798-1800	to	_
8-24	1801-1805	drug	_
8-25	1806-1809	and	_
8-26	1810-1817	alcohol	_
8-27	1818-1822	cues	_
8-28	1823-1825	in	_
8-29	1826-1840	frontostriatal	_
8-30	1841-1849	circuits	_
8-31	1850-1851	.	_

9-1	1852-1857	These	_
9-2	1858-1865	results	_
9-3	1866-1873	provide	_
9-4	1874-1876	an	_
9-5	1877-1886	empirical	_
9-6	1887-1897	foundation	_
9-7	1898-1901	for	_
9-8	1902-1908	future	_
9-9	1909-1917	clinical	_
9-10	1918-1924	trials	_
9-11	1925-1929	that	_
9-12	1930-1933	may	_
9-13	1934-1942	evaluate	_
9-14	1943-1946	the	_
9-15	1947-1955	efficacy	_
9-16	1956-1957	,	_
9-17	1958-1968	durability	_
9-18	1969-1970	,	_
9-19	1971-1974	and	_
9-20	1975-1983	clinical	_
9-21	1984-1996	implications	_
9-22	1997-1999	of	_
9-23	2000-2005	VMPFC	_
9-24	2006-2010	cTBS	_
9-25	2011-2013	to	_
9-26	2014-2019	treat	_
9-27	2020-2030	addictions	_
9-28	2031-2032	.	_

10-1	2033-2040	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	2041-2044	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	2045-2054	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	2055-2065	Experiment	_
10-5	2066-2067	1	http://maven.renci.org/NeuroBridge/neurobridge#1Level
10-6	2068-2069	(	_
10-7	2070-2077	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
10-8	2078-2083	Users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
10-9	2084-2085	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
10-10	2086-2089	and	_
10-11	2090-2100	Experiment	_
10-12	2101-2102	2	http://maven.renci.org/NeuroBridge/neurobridge#Bipolar_II_Disorder
10-13	2103-2104	(	_
10-14	2105-2110	Heavy	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
10-15	2111-2118	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
10-16	2119-2124	Users	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
10-17	2125-2126	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
10-18	2127-2139	Participants	_
10-19	2140-2141	.	_

11-1	2142-2163	Non–treatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-2	2164-2181	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-3	2182-2193	individuals	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-4	2194-2195	(	_
11-5	2196-2197	n	_
11-6	2198-2199	=	_
11-7	2200-2202	25	_
11-8	2203-2204	)	_
11-9	2205-2208	and	_
11-10	2209-2226	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
11-11	2227-2238	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
11-12	2239-2240	(	_
11-13	2241-2242	n	_
11-14	2243-2244	=	_
11-15	2245-2247	24	_
11-16	2248-2249	)	_
11-17	2250-2254	were	_
11-18	2255-2264	recruited	_
11-19	2265-2269	from	_
11-20	2270-2273	the	_
11-21	2274-2284	Charleston	_
11-22	2285-2286	,	_
11-23	2287-2292	South	_
11-24	2293-2301	Carolina	_
11-25	2302-2303	,	_
11-26	2304-2316	metropolitan	_
11-27	2317-2321	area	_
11-28	2322-2324	to	_
11-29	2325-2336	participate	_
11-30	2337-2339	in	_
11-31	2340-2343	one	_
11-32	2344-2346	of	_
11-33	2347-2350	two	_
11-34	2351-2365	single-blinded	_
11-35	2366-2367	,	_
11-36	2368-2374	active	_
11-37	2375-2390	sham–controlled	http://maven.renci.org/NeuroBridge/neurobridge#ControlledOralWordAssociationTestOfTheMultilingualAphasiaExamination
11-38	2391-2400	crossover	_
11-39	2401-2408	studies	_
11-40	2409-2410	.	_

12-1	2411-2416	These	_
12-2	2417-2424	studies	_
12-3	2425-2429	were	_
12-4	2430-2441	independent	_
12-5	2442-2445	but	_
12-6	2446-2450	were	_
12-7	2451-2454	run	_
12-8	2455-2457	in	_
12-9	2458-2466	parallel	_
12-10	2467-2469	by	_
12-11	2470-2473	the	_
12-12	2474-2478	same	_
12-13	2479-2484	study	_
12-14	2485-2496	coordinator	_
12-15	2497-2502	using	_
12-16	2503-2506	the	_
12-17	2507-2511	same	_
12-18	2512-2515	TMS	_
12-19	2516-2525	equipment	_
12-20	2526-2529	and	_
12-21	2530-2540	facilities	_
12-22	2541-2542	.	_

13-1	2543-2552	Following	_
13-2	2553-2561	informed	_
13-3	2562-2569	consent	_
13-4	2570-2580	procedures	_
13-5	2581-2589	approved	_
13-6	2590-2592	by	_
13-7	2593-2596	the	_
13-8	2597-2604	Medical	_
13-9	2605-2615	University	_
13-10	2616-2618	of	_
13-11	2619-2624	South	_
13-12	2625-2633	Carolina	_
13-13	2634-2647	Institutional	_
13-14	2648-2654	Review	_
13-15	2655-2660	Board	_
13-16	2661-2662	,	_
13-17	2663-2675	participants	_
13-18	2676-2685	completed	_
13-19	2686-2695	screening	_
13-20	2696-2707	assessments	_
13-21	2708-2715	related	_
13-22	2716-2718	to	_
13-23	2719-2722	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-24	2723-2726	and	_
13-25	2727-2730	TMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
13-26	2731-2739	protocol	_
13-27	2740-2746	safety	_
13-28	2747-2748	,	_
13-29	2749-2755	mental	_
13-30	2756-2762	status	_
13-31	2763-2764	,	_
13-32	2765-2768	and	_
13-33	2769-2773	drug	_
13-34	2774-2777	use	_
13-35	2778-2780	to	_
13-36	2781-2790	determine	_
13-37	2791-2796	study	_
13-38	2797-2808	eligibility	_
13-39	2809-2810	(	_
13-40	2811-2814	see	_
13-41	2815-2827	Supplemental	_
13-42	2828-2835	Methods	_
13-43	2836-2839	for	_
13-44	2840-2848	detailed	_
13-45	2849-2868	inclusion/exclusion	_
13-46	2869-2880	information	_
13-47	2881-2882	)	_
13-48	2883-2884	.	_

14-1	2885-2893	Eligible	_
14-2	2894-2906	participants	_
14-3	2907-2916	completed	_
14-4	2917-2920	two	_
14-5	2921-2929	MRI/rTMS	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-6	2930-2936	visits	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-7	2937-2938	(	_
14-8	2939-2943	each	_
14-9	2944-2946	~1	_
14-10	2947-2951	hour	_
14-11	2952-2953	)	_
14-12	2954-2955	.	_

15-1	2956-2962	Before	_
15-2	2963-2967	each	_
15-3	2968-2973	study	_
15-4	2974-2981	session	_
15-5	2982-2983	,	_
15-6	2984-2985	a	_
15-7	2986-2996	multipanel	_
15-8	2997-3002	urine	_
15-9	3003-3007	drug	_
15-10	3008-3014	screen	_
15-11	3015-3016	(	_
15-12	3017-3024	QuikVue	_
15-13	3025-3032	6-panel	_
15-14	3033-3038	urine	_
15-15	3039-3043	drug	_
15-16	3044-3050	screen	_
15-17	3051-3052	;	_
15-18	3053-3059	Quidel	_
15-19	3060-3061	,	_
15-20	3062-3065	San	_
15-21	3066-3071	Diego	_
15-22	3072-3073	,	_
15-23	3074-3076	CA	_
15-24	3077-3078	)	_
15-25	3079-3082	was	_
15-26	3083-3088	given	_
15-27	3089-3090	.	_

16-1	3091-3103	Participants	_
16-2	3104-3108	were	_
16-3	3109-3113	told	_
16-4	3114-3119	ahead	_
16-5	3120-3122	of	_
16-6	3123-3127	time	_
16-7	3128-3132	that	_
16-8	3133-3135	if	_
16-9	3136-3140	they	_
16-10	3141-3144	had	_
16-11	3145-3153	positive	_
16-12	3154-3159	urine	_
16-13	3160-3164	drug	_
16-14	3165-3171	screen	_
16-15	3172-3175	for	_
16-16	3176-3177	(	_
16-17	3178-3182	meth	_
16-18	3183-3184	)	_
16-19	3185-3196	amphetamine	_
16-20	3197-3198	,	_
16-21	3199-3206	opiates	_
16-22	3207-3208	,	_
16-23	3209-3218	marijuana	_
16-24	3219-3220	,	_
16-25	3221-3223	or	_
16-26	3224-3239	benzodiazepines	_
16-27	3240-3244	they	_
16-28	3245-3250	would	_
16-29	3251-3254	not	_
16-30	3255-3257	be	_
16-31	3258-3266	eligible	_
16-32	3267-3269	to	_
16-33	3270-3281	participate	_
16-34	3282-3284	on	_
16-35	3285-3289	that	_
16-36	3290-3293	day	_
16-37	3294-3297	and	_
16-38	3298-3302	that	_
16-39	3303-3307	they	_
16-40	3308-3313	would	_
16-41	3314-3318	have	_
16-42	3319-3322	one	_
16-43	3323-3334	opportunity	_
16-44	3335-3337	to	_
16-45	3338-3348	reschedule	_
16-46	3349-3350	.	_

17-1	3351-3353	In	_
17-2	3354-3358	this	_
17-3	3359-3364	study	_
17-4	3365-3366	,	_
17-5	3367-3371	none	_
17-6	3372-3374	of	_
17-7	3375-3378	the	_
17-8	3379-3391	participants	_
17-9	3392-3395	had	_
17-10	3396-3398	to	_
17-11	3399-3409	reschedule	_
17-12	3410-3413	for	_
17-13	3414-3415	a	_
17-14	3416-3424	positive	_
17-15	3425-3430	urine	_
17-16	3431-3435	drug	_
17-17	3436-3442	screen	_
17-18	3443-3444	.	_

18-1	3445-3448	All	_
18-2	3449-3461	participants	_
18-3	3462-3470	received	_
18-4	3471-3475	both	_
18-5	3476-3480	real	_
18-6	3481-3484	and	_
18-7	3485-3489	sham	_
18-8	3490-3495	VMPFC	_
18-9	3496-3500	cTBS	_
18-10	3501-3502	(	_
18-11	3503-3506	one	_
18-12	3507-3511	type	_
18-13	3512-3515	per	_
18-14	3516-3523	session	_
18-15	3524-3525	)	_
18-16	3526-3529	and	_
18-17	3530-3534	were	_
18-18	3535-3550	counterbalanced	_
18-19	3551-3554	for	_
18-20	3555-3558	the	_
18-21	3559-3564	order	_
18-22	3565-3567	in	_
18-23	3568-3573	which	_
18-24	3574-3578	they	_
18-25	3579-3587	received	_
18-26	3588-3599	stimulation	_
18-27	3600-3601	(	_
18-28	3602-3605	Fp1	_
18-29	3606-3614	landmark	_
18-30	3615-3620	based	_
18-31	3621-3623	on	_
18-32	3624-3627	the	_
18-33	3628-3641	International	_
18-34	3642-3647	10–20	_
18-35	3648-3654	system	_
18-36	3655-3656	;	_
18-37	3657-3660	110	_
18-38	3661-3662	%	_
18-39	3663-3670	resting	_
18-40	3671-3676	motor	_
18-41	3677-3686	threshold	_
18-42	3687-3688	[	_
18-43	3689-3692	rMT	_
18-44	3693-3694	]	_
18-45	3695-3696	;	_
18-46	3697-3700	six	_
18-47	3701-3709	sessions	_
18-48	3710-3712	of	_
18-49	3713-3717	cTBS	_
18-50	3718-3721	for	_
18-51	3722-3726	each	_
18-52	3727-3732	visit	_
18-53	3733-3734	;	_
18-54	3735-3739	3600	_
18-55	3740-3746	pulses	_
18-56	3747-3752	total	_
18-57	3753-3754	,	_
18-58	3755-3759	with	_
18-59	3760-3761	a	_
18-60	3762-3771	60-second	_
18-61	3772-3777	break	_
18-62	3778-3783	after	_
18-63	3784-3787	the	_
18-64	3788-3793	first	_
18-65	3794-3798	1800	_
18-66	3799-3805	pulses	_
18-67	3806-3807	)	_
18-68	3808-3809	.	_

19-1	3810-3815	Visit	_
19-2	3816-3817	2	_
19-3	3818-3826	occurred	_
19-4	3827-3834	between	_
19-5	3835-3836	7	_
19-6	3837-3840	and	_
19-7	3841-3843	14	_
19-8	3844-3848	days	_
19-9	3849-3854	after	_
19-10	3855-3860	visit	_
19-11	3861-3863	1.	_
19-12	3864-3868	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-13	3869-3881	drug/alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-14	3882-3885	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-15	3886-3896	reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-16	3897-3901	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-17	3902-3906	data	_
19-18	3907-3911	were	_
19-19	3912-3921	collected	_
19-20	3922-3933	immediately	_
19-21	3934-3940	before	_
19-22	3941-3944	and	_
19-23	3945-3950	after	_
19-24	3951-3955	cTBS	_
19-25	3956-3967	stimulation	_
19-26	3968-3969	(	_
19-27	3970-3976	Figure	_
19-28	3977-3978	1	_
19-29	3979-3980	)	_
19-30	3981-3982	,	_
19-31	3983-3987	with	_
19-32	3988-3991	the	_
19-33	3992-3996	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-34	3997-4001	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-35	4002-4011	initiated	_
19-36	4012-4018	within	_
19-37	4019-4021	20	_
19-38	4022-4029	minutes	_
19-39	4030-4032	of	_
19-40	4033-4042	receiving	_
19-41	4043-4047	real	_
19-42	4048-4050	or	_
19-43	4051-4055	sham	_
19-44	4056-4060	cTBS	_
19-45	4061-4064	and	_
19-46	4065-4074	completed	_
19-47	4075-4077	no	_
19-48	4078-4083	later	_
19-49	4084-4088	than	_
19-50	4089-4091	40	_
19-51	4092-4099	minutes	_
19-52	4100-4105	after	_
19-53	4106-4110	cTBS	_
19-54	4111-4113	to	_
19-55	4114-4122	maximize	_
19-56	4123-4131	presumed	_
19-57	4132-4139	effects	_
19-58	4140-4142	of	_
19-59	4143-4147	cTBS	_
19-60	4148-4150	on	_
19-61	4151-4159	cortical	_
19-62	4160-4168	activity	_
19-63	4169-4170	.	_

20-1	4171-4184	Self-reported	_
20-2	4185-4192	cocaine	_
20-3	4193-4195	or	_
20-4	4196-4203	alcohol	_
20-5	4204-4211	craving	_
20-6	4212-4213	(	_
20-7	4214-4226	respectively	_
20-8	4227-4228	)	_
20-9	4229-4232	was	_
20-10	4233-4241	assessed	_
20-11	4242-4244	at	_
20-12	4245-4249	five	_
20-13	4250-4254	time	_
20-14	4255-4261	points	_
20-15	4262-4263	:	_
20-16	4264-4268	upon	_
20-17	4269-4274	visit	_
20-18	4275-4285	initiation	_
20-19	4286-4287	,	_
20-20	4288-4294	before	_
20-21	4295-4298	the	_
20-22	4299-4307	baseline	_
20-23	4308-4312	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
20-24	4313-4317	scan	_
20-25	4318-4319	,	_
20-26	4320-4326	before	_
20-27	4327-4330	the	_
20-28	4331-4335	cTBS	_
20-29	4336-4343	session	_
20-30	4344-4345	,	_
20-31	4346-4357	immediately	_
20-32	4358-4363	after	_
20-33	4364-4368	cTBS	_
20-34	4369-4370	,	_
20-35	4371-4374	and	_
20-36	4375-4380	after	_
20-37	4381-4384	the	_
20-38	4385-4391	second	_
20-39	4392-4396	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
20-40	4397-4401	scan	_
20-41	4402-4403	.	_

21-1	4404-4414	Procedures	_
21-2	4415-4416	:	_
21-3	4417-4425	Clinical	_
21-4	4426-4437	Assessments	_
21-5	4438-4439	.	_

22-1	4440-4451	Self-report	_
22-2	4452-4463	assessments	_
22-3	4464-4472	included	_
22-4	4473-4476	the	_
22-5	4477-4487	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-6	4488-4496	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-7	4497-4506	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-8	4507-4510	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-9	4511-4517	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-10	4518-4519	,	_
22-11	4520-4528	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
22-12	4529-4539	Followback	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
22-13	4540-4541	[	_
22-14	4542-4545	for	_
22-15	4546-4553	cocaine	_
22-16	4554-4555	,	_
22-17	4556-4563	alcohol	_
22-18	4564-4565	,	_
22-19	4566-4575	marijuana	_
22-20	4576-4577	,	_
22-21	4578-4581	and	_
22-22	4582-4590	nicotine	_
22-23	4591-4592	]	_
22-24	4593-4594	,	_
22-25	4595-4602	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
22-26	4603-4606	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
22-27	4607-4616	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
22-28	4617-4631	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
22-29	4632-4636	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
22-30	4637-4638	,	_
22-31	4639-4649	Fagerström	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
22-32	4650-4657	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
22-33	4658-4667	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
22-34	4668-4669	,	_
22-35	4670-4674	Beck	_
22-36	4675-4685	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
22-37	4686-4698	Inventory-II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
22-38	4699-4700	,	_
22-39	4701-4704	and	_
22-40	4705-4716	State-Trait	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
22-41	4717-4724	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
22-42	4725-4734	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
22-43	4735-4736	.	_

23-1	4737-4745	Timeline	_
23-2	4746-4756	Followback	_
23-3	4757-4760	was	_
23-4	4761-4765	used	_
23-5	4766-4768	to	_
23-6	4769-4777	evaluate	_
23-7	4778-4782	past	_
23-8	4783-4787	week	_
23-9	4788-4789	’	_
23-10	4790-4791	s	_
23-11	4792-4801	substance	_
23-12	4802-4805	use	_
23-13	4806-4808	at	_
23-14	4809-4812	all	_
23-15	4813-4818	study	_
23-16	4819-4825	visits	_
23-17	4826-4827	.	_

24-1	4828-4830	As	_
24-2	4831-4840	typically	_
24-3	4841-4845	done	_
24-4	4846-4848	in	_
24-5	4849-4860	cue-induced	_
24-6	4861-4868	craving	_
24-7	4869-4876	studies	_
24-8	4877-4878	,	_
24-9	4879-4884	study	_
24-10	4885-4894	personnel	_
24-11	4895-4902	ensured	_
24-12	4903-4907	that	_
24-13	4908-4915	craving	_
24-14	4916-4922	levels	_
24-15	4923-4927	were	_
24-16	4928-4930	at	_
24-17	4931-4933	or	_
24-18	4934-4939	below	_
24-19	4940-4948	baseline	_
24-20	4949-4955	before	_
24-21	4956-4968	participants	_
24-22	4969-4973	were	_
24-23	4974-4983	dismissed	_
24-24	4984-4988	from	_
24-25	4989-4993	each	_
24-26	4994-4999	visit	_
24-27	5000-5001	.	_

25-1	5002-5012	Procedures	_
25-2	5013-5014	:	_
25-3	5015-5027	Drug/Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-4	5028-5031	Cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-5	5032-5042	Reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-6	5043-5047	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-7	5048-5052	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-8	5053-5054	.	_

26-1	5055-5058	The	_
26-2	5059-5071	drug/alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-3	5072-5075	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-4	5076-5086	reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-5	5087-5091	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-6	5092-5096	that	_
26-7	5097-5100	has	_
26-8	5101-5105	been	_
26-9	5106-5110	used	_
26-10	5111-5113	by	_
26-11	5114-5117	our	_
26-12	5118-5123	group	_
26-13	5124-5126	in	_
26-14	5127-5130	the	_
26-15	5131-5135	past	_
26-16	5136-5139	was	_
26-17	5140-5152	administered	_
26-18	5153-5155	in	_
26-19	5156-5159	the	_
26-20	5160-5163	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
26-21	5164-5171	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
26-22	5172-5174	as	_
26-23	5175-5176	a	_
26-24	5177-5182	block	_
26-25	5183-5189	design	_
26-26	5190-5195	using	_
26-27	5196-5203	E-Prime	_
26-28	5204-5205	2	_
26-29	5206-5214	software	_
26-30	5215-5216	(	_
26-31	5217-5227	Psychology	_
26-32	5228-5236	Software	_
26-33	5237-5242	Tools	_
26-34	5243-5244	,	_
26-35	5245-5249	Inc.	_
26-36	5250-5251	,	_
26-37	5252-5262	Sharpsburg	_
26-38	5263-5264	,	_
26-39	5265-5267	PA	_
26-40	5268-5269	)	_
26-41	5270-5271	.	_

27-1	5272-5275	The	_
27-2	5276-5281	total	_
27-3	5282-5286	task	_
27-4	5287-5291	time	_
27-5	5292-5295	was	_
27-6	5296-5298	12	_
27-7	5299-5306	minutes	_
27-8	5307-5310	and	_
27-9	5311-5320	consisted	_
27-10	5321-5323	of	_
27-11	5324-5327	six	_
27-12	5328-5338	120-second	_
27-13	5339-5345	epochs	_
27-14	5346-5347	.	_

28-1	5348-5352	Each	_
28-2	5353-5358	epoch	_
28-3	5359-5367	included	_
28-4	5368-5379	alternating	_
28-5	5380-5389	24-second	_
28-6	5390-5396	blocks	_
28-7	5397-5399	of	_
28-8	5400-5404	four	_
28-9	5405-5409	task	_
28-10	5410-5420	conditions	_
28-11	5421-5422	:	_
28-12	5423-5427	drug	_
28-13	5428-5429	,	_
28-14	5430-5437	neutral	_
28-15	5438-5439	,	_
28-16	5440-5444	blur	_
28-17	5445-5446	,	_
28-18	5447-5450	and	_
28-19	5451-5455	rest	_
28-20	5456-5457	.	_

29-1	5458-5470	Respectively	_
29-2	5471-5472	,	_
29-3	5473-5478	these	_
29-4	5479-5483	task	_
29-5	5484-5494	conditions	_
29-6	5495-5503	included	_
29-7	5504-5510	images	_
29-8	5511-5513	of	_
29-9	5514-5522	cocaine-	_
29-10	5523-5525	or	_
29-11	5526-5541	alcohol-related	_
29-12	5542-5549	stimuli	_
29-13	5550-5560	customized	_
29-14	5561-5564	for	_
29-15	5565-5569	each	_
29-16	5570-5575	group	_
29-17	5576-5577	(	_
29-18	5578-5582	e.g.	_
29-19	5583-5584	,	_
29-20	5585-5590	crack	_
29-21	5591-5595	pipe	_
29-22	5596-5599	for	_
29-23	5600-5607	cocaine	_
29-24	5608-5613	users	_
29-25	5614-5615	,	_
29-26	5616-5622	liquor	_
29-27	5623-5630	bottles	_
29-28	5631-5634	for	_
29-29	5635-5642	alcohol	_
29-30	5643-5648	users	_
29-31	5649-5650	)	_
29-32	5651-5652	,	_
29-33	5653-5660	neutral	_
29-34	5661-5668	stimuli	_
29-35	5669-5670	(	_
29-36	5671-5675	e.g.	_
29-37	5676-5677	,	_
29-38	5678-5683	glass	_
29-39	5684-5686	of	_
29-40	5687-5692	water	_
29-41	5693-5694	,	_
29-42	5695-5702	cooking	_
29-43	5703-5711	utensils	_
29-44	5712-5713	,	_
29-45	5714-5720	people	_
29-46	5721-5727	eating	_
29-47	5728-5734	dinner	_
29-48	5735-5736	)	_
29-49	5737-5738	,	_
29-50	5739-5746	blurred	_
29-51	5747-5754	stimuli	_
29-52	5755-5761	acting	_
29-53	5762-5764	as	_
29-54	5765-5771	visual	_
29-55	5772-5780	controls	_
29-56	5781-5783	by	_
29-57	5784-5792	matching	_
29-58	5793-5802	substance	_
29-59	5803-5809	images	_
29-60	5810-5812	in	_
29-61	5813-5818	color	_
29-62	5819-5822	and	_
29-63	5823-5826	hue	_
29-64	5827-5828	,	_
29-65	5829-5832	and	_
29-66	5833-5834	a	_
29-67	5835-5843	fixation	_
29-68	5844-5849	cross	_
29-69	5850-5853	for	_
29-70	5854-5859	alert	_
29-71	5860-5864	rest	_
29-72	5865-5872	periods	_
29-73	5873-5874	.	_

30-1	5875-5881	During	_
30-2	5882-5886	each	_
30-3	5887-5891	task	_
30-4	5892-5897	block	_
30-5	5898-5899	,	_
30-6	5900-5904	five	_
30-7	5905-5911	images	_
30-8	5912-5916	were	_
30-9	5917-5926	presented	_
30-10	5927-5928	(	_
30-11	5929-5932	4.8	_
30-12	5933-5940	seconds	_
30-13	5941-5942	)	_
30-14	5943-5944	.	_

31-1	5945-5955	Procedures	_
31-2	5956-5957	:	_
31-3	5958-5970	Neuroimaging	_
31-4	5971-5982	Acquisition	_
31-5	5983-5984	.	_

32-1	5985-5997	Participants	_
32-2	5998-6002	were	_
32-3	6003-6010	scanned	_
32-4	6011-6016	using	_
32-5	6017-6018	a	_
32-6	6019-6026	Siemens	_
32-7	6027-6031	3.0T	_
32-8	6032-6035	TIM	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
32-9	6036-6040	Trio	_
32-10	6041-6042	(	_
32-11	6043-6050	Siemens	_
32-12	6051-6056	Corp.	_
32-13	6057-6058	,	_
32-14	6059-6067	Erlangen	_
32-15	6068-6069	,	_
32-16	6070-6077	Germany	_
32-17	6078-6079	)	_
32-18	6080-6083	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-19	6084-6091	scanner	_
32-20	6092-6096	with	_
32-21	6097-6098	a	_
32-22	6099-6109	32-channel	_
32-23	6110-6114	head	_
32-24	6115-6119	coil	_
32-25	6120-6121	.	_

33-1	6122-6137	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
33-2	6138-6149	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-3	6150-6160	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-4	6161-6167	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-5	6168-6172	were	_
33-6	6173-6181	acquired	_
33-7	6182-6187	using	_
33-8	6188-6189	a	_
33-9	6190-6203	magnetization	_
33-10	6204-6212	prepared	_
33-11	6213-6218	rapid	_
33-12	6219-6230	acquisition	_
33-13	6231-6244	gradient-echo	_
33-14	6245-6253	sequence	_
33-15	6254-6255	(	_
33-16	6256-6266	repetition	_
33-17	6267-6276	time/echo	_
33-18	6277-6281	time	_
33-19	6282-6283	=	_
33-20	6284-6288	1900	_
33-21	6289-6296	ms/2.34	_
33-22	6297-6299	ms	_
33-23	6300-6301	;	_
33-24	6302-6307	field	_
33-25	6308-6310	of	_
33-26	6311-6315	view	_
33-27	6316-6317	=	_
33-28	6318-6321	220	_
33-29	6322-6324	mm	_
33-30	6325-6326	;	_
33-31	6327-6333	matrix	_
33-32	6334-6335	=	_
33-33	6336-6339	256	_
33-34	6340-6341	×	_
33-35	6342-6345	256	_
33-36	6346-6352	voxels	_
33-37	6353-6354	;	_
33-38	6355-6358	192	_
33-39	6359-6365	slices	_
33-40	6366-6367	;	_
33-41	6368-6373	slice	_
33-42	6374-6383	thickness	_
33-43	6384-6385	=	_
33-44	6386-6389	1.0	_
33-45	6390-6392	mm	_
33-46	6393-6397	with	_
33-47	6398-6400	no	_
33-48	6401-6404	gap	_
33-49	6405-6406	;	_
33-50	6407-6412	final	_
33-51	6413-6423	resolution	_
33-52	6424-6425	=	_
33-53	6426-6431	1-mm3	_
33-54	6432-6438	voxels	_
33-55	6439-6440	)	_
33-56	6441-6442	.	_

34-1	6443-6453	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-2	6454-6460	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-3	6461-6465	were	_
34-4	6466-6474	acquired	_
34-5	6475-6479	with	_
34-6	6480-6481	a	_
34-7	6482-6492	multislice	_
34-8	6493-6506	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-9	6507-6518	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-10	6519-6526	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-11	6527-6528	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-12	6529-6532	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-13	6533-6534	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-14	6535-6543	sequence	_
34-15	6544-6545	(	_
34-16	6546-6556	repetition	_
34-17	6557-6566	time/echo	_
34-18	6567-6571	time	_
34-19	6572-6573	=	_
34-20	6574-6578	2200	_
34-21	6579-6584	ms/35	_
34-22	6585-6587	ms	_
34-23	6588-6589	;	_
34-24	6590-6595	field	_
34-25	6596-6598	of	_
34-26	6599-6603	view	_
34-27	6604-6605	=	_
34-28	6606-6609	192	_
34-29	6610-6612	mm	_
34-30	6613-6614	;	_
34-31	6615-6621	matrix	_
34-32	6622-6623	=	_
34-33	6624-6626	64	_
34-34	6627-6628	×	_
34-35	6629-6631	64	_
34-36	6632-6638	voxels	_
34-37	6639-6640	;	_
34-38	6641-6643	36	_
34-39	6644-6650	slices	_
34-40	6651-6652	;	_
34-41	6653-6658	slice	_
34-42	6659-6668	thickness	_
34-43	6669-6670	=	_
34-44	6671-6672	3	_
34-45	6673-6675	mm	_
34-46	6676-6680	with	_
34-47	6681-6683	no	_
34-48	6684-6687	gap	_
34-49	6688-6689	;	_
34-50	6690-6695	final	_
34-51	6696-6706	resolution	_
34-52	6707-6708	=	_
34-53	6709-6710	3	_
34-54	6711-6714	mm3	_
34-55	6715-6721	voxels	_
34-56	6722-6723	)	_
34-57	6724-6725	.	_

35-1	6726-6730	Each	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-2	6731-6741	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-3	6742-6745	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-4	6746-6755	consisted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-5	6756-6758	of	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-6	6759-6762	328	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-7	6763-6767	time	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-8	6768-6774	points	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-9	6775-6776	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging

36-1	6777-6787	Procedures	_
36-2	6788-6789	:	_
36-3	6790-6794	cTBS	_
36-4	6795-6808	Protocol—Real	_
36-5	6809-6812	and	_
36-6	6813-6817	Sham	_
36-7	6818-6822	cTBS	_
36-8	6823-6824	.	_

37-1	6825-6829	Coil	_
37-2	6830-6838	position	_
37-3	6839-6842	was	_
37-4	6843-6853	determined	_
37-5	6854-6859	using	_
37-6	6860-6872	standardized	_
37-7	6873-6884	coordinates	_
37-8	6885-6889	from	_
37-9	6890-6893	the	_
37-10	6894-6907	International	_
37-11	6908-6913	10–20	_
37-12	6914-6920	system	_
37-13	6921-6922	(	_
37-14	6923-6927	with	_
37-15	6928-6931	Fp1	_
37-16	6932-6945	corresponding	_
37-17	6946-6948	to	_
37-18	6949-6952	the	_
37-19	6953-6957	left	_
37-20	6958-6963	VMPFC	_
37-21	6964-6975	stimulation	_
37-22	6976-6982	target	_
37-23	6983-6984	)	_
37-24	6985-6986	.	_

38-1	6987-6990	The	_
38-2	6991-6999	location	_
38-3	7000-7003	and	_
38-4	7004-7015	orientation	_
38-5	7016-7018	of	_
38-6	7019-7023	each	_
38-7	7024-7035	participant	_
38-8	7036-7037	’	_
38-9	7038-7039	s	_
38-10	7040-7044	coil	_
38-11	7045-7054	placement	_
38-12	7055-7058	was	_
38-13	7059-7068	indicated	_
38-14	7069-7071	on	_
38-15	7072-7073	a	_
38-16	7074-7079	nylon	_
38-17	7080-7083	cap	_
38-18	7084-7088	that	_
38-19	7089-7101	participants	_
38-20	7102-7106	wore	_
38-21	7107-7117	throughout	_
38-22	7118-7123	visit	_
38-23	7124-7125	1	_
38-24	7126-7129	and	_
38-25	7130-7134	both	_
38-26	7135-7143	MRI/rTMS	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-27	7144-7152	sessions	_
38-28	7153-7154	.	_

39-1	7155-7167	Participants	_
39-2	7168-7169	’	_
39-3	7170-7173	rMT	_
39-4	7174-7177	was	_
39-5	7178-7188	identified	_
39-6	7189-7192	via	_
39-7	7193-7196	the	_
39-8	7197-7209	standardized	_
39-9	7210-7220	Parametric	_
39-10	7221-7231	Estimation	_
39-11	7232-7234	by	_
39-12	7235-7245	Sequential	_
39-13	7246-7253	Testing	_
39-14	7254-7263	procedure	_
39-15	7264-7265	.	_

40-1	7266-7269	The	_
40-2	7270-7274	cTBS	_
40-3	7275-7278	was	_
40-4	7279-7291	administered	_
40-5	7292-7296	with	_
40-6	7297-7298	a	_
40-7	7299-7314	figure-of-eight	_
40-8	7315-7323	Cool-B65	_
40-9	7324-7327	A/P	_
40-10	7328-7332	coil	_
40-11	7333-7334	(	_
40-12	7335-7345	MagVenture	_
40-13	7346-7347	,	_
40-14	7348-7353	Farum	_
40-15	7354-7355	,	_
40-16	7356-7363	Denmark	_
40-17	7364-7365	)	_
40-18	7366-7367	.	_

41-1	7368-7380	Participants	_
41-2	7381-7389	received	_
41-3	7390-7393	two	_
41-4	7394-7402	2-minute	_
41-5	7403-7409	trains	_
41-6	7410-7412	of	_
41-7	7413-7417	cTBS	_
41-8	7418-7422	over	_
41-9	7423-7426	Fp1	_
41-10	7427-7428	(	_
41-11	7429-7432	one	_
41-12	7433-7438	train	_
41-13	7439-7440	=	_
41-14	7441-7444	120	_
41-15	7445-7452	seconds	_
41-16	7453-7454	;	_
41-17	7455-7460	three	_
41-18	7461-7466	pulse	_
41-19	7467-7473	bursts	_
41-20	7474-7476	at	_
41-21	7477-7478	5	_
41-22	7479-7481	Hz	_
41-23	7482-7483	;	_
41-24	7484-7486	15	_
41-25	7487-7495	pulses/s	_
41-26	7496-7497	;	_
41-27	7498-7502	1800	_
41-28	7503-7515	pulses/train	_
41-29	7516-7517	;	_
41-30	7518-7527	60-second	_
41-31	7528-7538	intertrain	_
41-32	7539-7547	interval	_
41-33	7548-7549	;	_
41-34	7550-7553	110	_
41-35	7554-7555	%	_
41-36	7556-7559	rMT	_
41-37	7560-7561	)	_
41-38	7562-7563	(	_
41-39	7564-7567	see	_
41-40	7568-7580	Supplemental	_
41-41	7581-7588	Methods	_
41-42	7589-7592	for	_
41-43	7593-7600	details	_
41-44	7601-7603	of	_
41-45	7604-7612	rigorous	_
41-46	7613-7619	active	_
41-47	7620-7624	sham	_
41-48	7625-7626	)	_
41-49	7627-7628	.	_

42-1	7629-7631	To	_
42-2	7632-7639	enhance	_
42-3	7640-7652	tolerability	_
42-4	7653-7654	,	_
42-5	7655-7666	stimulation	_
42-6	7667-7676	intensity	_
42-7	7677-7680	was	_
42-8	7681-7690	gradually	_
42-9	7691-7700	escalated	_
42-10	7701-7703	in	_
42-11	7704-7705	5	_
42-12	7706-7707	%	_
42-13	7708-7718	increments	_
42-14	7719-7720	(	_
42-15	7721-7725	from	_
42-16	7726-7728	80	_
42-17	7729-7730	%	_
42-18	7731-7733	to	_
42-19	7734-7737	110	_
42-20	7738-7739	%	_
42-21	7740-7743	rMT	_
42-22	7744-7745	)	_
42-23	7746-7750	over	_
42-24	7751-7754	the	_
42-25	7755-7760	first	_
42-26	7761-7763	30	_
42-27	7764-7771	seconds	_
42-28	7772-7774	of	_
42-29	7775-7779	each	_
42-30	7780-7785	train	_
42-31	7786-7787	.	_

43-1	7788-7798	Procedures	_
43-2	7799-7800	:	_
43-3	7801-7804	Cue	_
43-4	7805-7817	Recollection	_
43-5	7818-7824	During	_
43-6	7825-7829	cTBS	_
43-7	7830-7844	Administration	_
43-8	7845-7846	.	_

44-1	7847-7853	Before	_
44-2	7854-7858	cTBS	_
44-3	7859-7873	administration	_
44-4	7874-7875	,	_
44-5	7876-7888	participants	_
44-6	7889-7893	were	_
44-7	7894-7899	asked	_
44-8	7900-7902	to	_
44-9	7903-7909	recall	_
44-10	7910-7913	the	_
44-11	7914-7918	last	_
44-12	7919-7923	time	_
44-13	7924-7928	they	_
44-14	7929-7933	used	_
44-15	7934-7941	cocaine	_
44-16	7942-7944	or	_
44-17	7945-7952	alcohol	_
44-18	7953-7954	(	_
44-19	7955-7967	respectively	_
44-20	7968-7969	)	_
44-21	7970-7973	and	_
44-22	7974-7975	,	_
44-23	7976-7981	using	_
44-24	7982-7983	a	_
44-25	7984-7990	series	_
44-26	7991-7993	of	_
44-27	7994-8006	standardized	_
44-28	8007-8016	questions	_
44-29	8017-8021	from	_
44-30	8022-8033	traditional	_
44-31	8034-8043	Narrative	_
44-32	8044-8052	Exposure	_
44-33	8053-8060	Therapy	_
44-34	8061-8069	practice	_
44-35	8070-8071	,	_
44-36	8072-8076	they	_
44-37	8077-8081	were	_
44-38	8082-8087	asked	_
44-39	8088-8090	to	_
44-40	8091-8099	describe	_
44-41	8100-8103	the	_
44-42	8104-8109	place	_
44-43	8110-8114	they	_
44-44	8115-8119	were	_
44-45	8120-8125	using	_
44-46	8126-8127	,	_
44-47	8128-8129	a	_
44-48	8130-8136	visual	_
44-49	8137-8148	description	_
44-50	8149-8151	of	_
44-51	8152-8155	the	_
44-52	8156-8161	scene	_
44-53	8162-8163	,	_
44-54	8164-8167	and	_
44-55	8168-8169	a	_
44-56	8170-8181	description	_
44-57	8182-8184	of	_
44-58	8185-8188	the	_
44-59	8189-8196	sensory	_
44-60	8197-8207	properties	_
44-61	8208-8210	of	_
44-62	8211-8214	the	_
44-63	8215-8219	drug	_
44-64	8220-8229	including	_
44-65	8230-8235	taste	_
44-66	8236-8237	,	_
44-67	8238-8243	smell	_
44-68	8244-8245	,	_
44-69	8246-8249	and	_
44-70	8250-8259	sensation	_
44-71	8260-8261	.	_

45-1	8262-8268	During	_
45-2	8269-8273	cTBS	_
45-3	8274-8288	administration	_
45-4	8289-8290	,	_
45-5	8291-8294	the	_
45-6	8295-8307	participants	_
45-7	8308-8312	were	_
45-8	8313-8319	primed	_
45-9	8320-8325	every	_
45-10	8326-8328	20	_
45-11	8329-8336	seconds	_
45-12	8337-8339	to	_
45-13	8340-8341	“	_
45-14	8342-8347	Think	_
45-15	8348-8353	about	_
45-16	8354-8358	that	_
45-17	8359-8364	scene	_
45-18	8365-8368	you	_
45-19	8369-8378	described	_
45-20	8379-8386	wherein	_
45-21	8387-8390	you	_
45-22	8391-8395	were	_
45-23	8396-8400	last	_
45-24	8401-8406	using	_
45-25	8407-8422	cocaine/alcohol	_
45-26	8423-8424	”	_
45-27	8425-8426	(	_
45-28	8427-8438	paraphrased	_
45-29	8439-8441	so	_
45-30	8442-8444	as	_
45-31	8445-8447	to	_
45-32	8448-8450	be	_
45-33	8451-8459	tailored	_
45-34	8460-8462	to	_
45-35	8463-8466	the	_
45-36	8467-8478	participant	_
45-37	8479-8480	’	_
45-38	8481-8482	s	_
45-39	8483-8494	description	_
45-40	8495-8496	)	_
45-41	8497-8498	.	_

46-1	8499-8503	Data	_
46-2	8504-8512	Analysis	_
46-3	8513-8526	Self-reported	_
46-4	8527-8534	Craving	_
46-5	8535-8536	.	_

47-1	8537-8550	Self-reported	_
47-2	8551-8558	craving	_
47-3	8559-8565	scores	_
47-4	8566-8570	were	_
47-5	8571-8578	entered	_
47-6	8579-8583	into	_
47-7	8584-8585	a	_
47-8	8586-8593	two-way	_
47-9	8594-8602	analysis	_
47-10	8603-8605	of	_
47-11	8606-8614	variance	_
47-12	8615-8616	(	_
47-13	8617-8622	ANOVA	_
47-14	8623-8624	)	_
47-15	8625-8626	(	_
47-16	8627-8636	treatment	_
47-17	8637-8641	type	_
47-18	8642-8643	[	_
47-19	8644-8653	real/sham	_
47-20	8654-8655	]	_
47-21	8656-8657	×	_
47-22	8658-8662	time	_
47-23	8663-8664	[	_
47-24	8665-8673	pre/post	_
47-25	8674-8675	]	_
47-26	8676-8677	)	_
47-27	8678-8681	and	_
47-28	8682-8692	subsequent	_
47-29	8693-8694	t	_
47-30	8695-8700	tests	_
47-31	8701-8703	to	_
47-32	8704-8713	determine	_
47-33	8714-8717	the	_
47-34	8718-8724	effect	_
47-35	8725-8727	of	_
47-36	8728-8737	treatment	_
47-37	8738-8740	on	_
47-38	8741-8748	changes	_
47-39	8749-8751	in	_
47-40	8752-8759	craving	_
47-41	8760-8761	.	_

48-1	8762-8774	Neuroimaging	_
48-2	8775-8788	Preprocessing	_
48-3	8789-8790	.	_

49-1	8791-8794	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
49-2	8795-8799	data	_
49-3	8800-8804	were	_
49-4	8805-8817	preprocessed	_
49-5	8818-8823	using	_
49-6	8824-8832	standard	_
49-7	8833-8842	protocols	_
49-8	8843-8846	via	_
49-9	8847-8852	SPM12	_
49-10	8853-8854	(	_
49-11	8855-8863	Wellcome	_
49-12	8864-8874	Department	_
49-13	8875-8877	of	_
49-14	8878-8887	Cognitive	_
49-15	8888-8897	Neurology	_
49-16	8898-8899	,	_
49-17	8900-8906	London	_
49-18	8907-8908	,	_
49-19	8909-8915	United	_
49-20	8916-8923	Kingdom	_
49-21	8924-8925	)	_
49-22	8926-8937	implemented	_
49-23	8938-8940	in	_
49-24	8941-8947	MATLAB	_
49-25	8948-8952	7.14	_
49-26	8953-8954	(	_
49-27	8955-8958	The	_
49-28	8959-8968	MathWorks	_
49-29	8969-8970	,	_
49-30	8971-8975	Inc.	_
49-31	8976-8977	,	_
49-32	8978-8984	Natick	_
49-33	8985-8986	,	_
49-34	8987-8989	MA	_
49-35	8990-8991	)	_
49-36	8992-8993	(	_
49-37	8994-8997	see	_
49-38	8998-9010	Supplemental	_
49-39	9011-9018	Methods	_
49-40	9019-9022	for	_
49-41	9023-9036	preprocessing	_
49-42	9037-9044	details	_
49-43	9045-9046	)	_
49-44	9047-9048	.	_

50-1	9049-9053	Data	_
50-2	9054-9062	analyses	_
50-3	9063-9067	were	_
50-4	9068-9077	conducted	_
50-5	9078-9080	on	_
50-6	9081-9082	a	_
50-7	9083-9088	total	_
50-8	9089-9091	of	_
50-9	9092-9094	49	_
50-10	9095-9107	participants	_
50-11	9108-9109	(	_
50-12	9110-9112	30	_
50-13	9113-9116	men	_
50-14	9117-9118	;	_
50-15	9119-9123	mean	_
50-16	9124-9127	age	_
50-17	9128-9129	=	_
50-18	9130-9132	34	_
50-19	9133-9134	±	_
50-20	9135-9137	11	_
50-21	9138-9143	years	_
50-22	9144-9145	;	_
50-23	9146-9149	age	_
50-24	9150-9155	range	_
50-25	9156-9157	=	_
50-26	9158-9163	21–54	_
50-27	9164-9169	years	_
50-28	9170-9171	)	_
50-29	9172-9173	(	_
50-30	9174-9177	see	_
50-31	9178-9183	Table	_
50-32	9184-9185	1	_
50-33	9186-9189	for	_
50-34	9190-9198	detailed	_
50-35	9199-9211	demographics	_
50-36	9212-9213	)	_
50-37	9214-9215	.	_

51-1	9216-9227	Generalized	_
51-2	9228-9247	Psychophysiological	_
51-3	9248-9259	Interaction	_
51-4	9260-9261	.	_

52-1	9262-9273	Generalized	_
52-2	9274-9293	psychophysiological	_
52-3	9294-9305	interaction	_
52-4	9306-9307	(	_
52-5	9308-9312	gPPI	_
52-6	9313-9314	)	_
52-7	9315-9318	was	_
52-8	9319-9323	used	_
52-9	9324-9326	to	_
52-10	9327-9338	investigate	_
52-11	9339-9353	task-modulated	_
52-12	9354-9362	patterns	_
52-13	9363-9365	of	_
52-14	9366-9368	FC	_
52-15	9369-9376	between	_
52-16	9377-9380	the	_
52-17	9381-9386	VMPFC	_
52-18	9387-9390	and	_
52-19	9391-9396	eight	_
52-20	9397-9404	regions	_
52-21	9405-9407	of	_
52-22	9408-9416	interest	_
52-23	9417-9418	(	_
52-24	9419-9423	ROIs	_
52-25	9424-9425	)	_
52-26	9426-9432	during	_
52-27	9433-9436	the	_
52-28	9437-9449	drug/alcohol	_
52-29	9450-9453	cue	_
52-30	9454-9464	reactivity	_
52-31	9465-9469	task	_
52-32	9470-9471	.	_

53-1	9472-9476	gPPI	_
53-2	9477-9480	was	_
53-3	9481-9490	conducted	_
53-4	9491-9493	as	_
53-5	9494-9503	described	_
53-6	9504-9506	by	_
53-7	9507-9514	McLaren	_
53-8	9515-9517	et	_
53-9	9518-9520	al	_
53-10	9521-9522	.	_

54-1	9523-9524	(	_
54-2	9525-9528	see	_
54-3	9529-9541	Supplemental	_
54-4	9542-9549	Methods	_
54-5	9550-9553	for	_
54-6	9554-9558	gPPI	_
54-7	9559-9567	analysis	_
54-8	9568-9575	details	_
54-9	9576-9577	)	_
54-10	9578-9579	.	_

55-1	9580-9582	We	_
55-2	9583-9591	computed	_
55-3	9592-9604	drug/alcohol	_
55-4	9605-9608	cue	_
55-5	9609-9614	minus	_
55-6	9615-9622	neutral	_
55-7	9623-9626	cue	_
55-8	9627-9628	“	_
55-9	9629-9637	contrast	_
55-10	9638-9643	betas	_
55-11	9644-9645	”	_
55-12	9646-9656	indicating	_
55-13	9657-9660	the	_
55-14	9661-9669	relative	_
55-15	9670-9672	FC	_
55-16	9673-9679	during	_
55-17	9680-9684	drug	_
55-18	9685-9691	versus	_
55-19	9692-9699	neutral	_
55-20	9700-9710	conditions	_
55-21	9711-9712	.	_

56-1	9713-9717	Four	_
56-2	9718-9726	contrast	_
56-3	9727-9732	betas	_
56-4	9733-9737	were	_
56-5	9738-9746	computed	_
56-6	9747-9748	:	_
56-7	9749-9756	prereal	_
56-8	9757-9761	cTBS	_
56-9	9762-9763	,	_
56-10	9764-9772	postreal	_
56-11	9773-9777	cTBS	_
56-12	9778-9779	,	_
56-13	9780-9787	presham	_
56-14	9788-9789	,	_
56-15	9790-9793	and	_
56-16	9794-9802	postsham	_
56-17	9803-9804	.	_

57-1	9805-9807	We	_
57-2	9808-9813	aimed	_
57-3	9814-9816	to	_
57-4	9817-9821	show	_
57-5	9822-9826	that	_
57-6	9827-9829	FC	_
57-7	9830-9837	between	_
57-8	9838-9841	the	_
57-9	9842-9847	VMPFC	_
57-10	9848-9851	and	_
57-11	9852-9859	several	_
57-12	9860-9868	striatal	_
57-13	9869-9872	and	_
57-14	9873-9881	salience	_
57-15	9882-9889	regions	_
57-16	9890-9895	would	_
57-17	9896-9904	decrease	_
57-18	9905-9911	during	_
57-19	9912-9924	drug/alcohol	_
57-20	9925-9928	cue	_
57-21	9929-9935	versus	_
57-22	9936-9943	neutral	_
57-23	9944-9947	cue	_
57-24	9948-9956	exposure	_
57-25	9957-9966	following	_
57-26	9967-9971	real	_
57-27	9972-9975	but	_
57-28	9976-9979	not	_
57-29	9980-9984	sham	_
57-30	9985-9990	VMPFC	_
57-31	9991-9995	cTBS	_
57-32	9996-9997	.	_

58-1	9998-10000	To	_
58-2	10001-10003	do	_
58-3	10004-10008	this	_
58-4	10009-10010	,	_
58-5	10011-10013	we	_
58-6	10014-10023	conducted	_
58-7	10024-10025	a	_
58-8	10026-10035	three-way	_
58-9	10036-10053	repeated-measures	_
58-10	10054-10059	ANOVA	_
58-11	10060-10069	involving	_
58-12	10070-10079	treatment	_
58-13	10080-10084	type	_
58-14	10085-10086	(	_
58-15	10087-10091	real	_
58-16	10092-10095	vs.	_
58-17	10096-10100	sham	_
58-18	10101-10102	)	_
58-19	10103-10104	,	_
58-20	10105-10109	time	_
58-21	10110-10111	(	_
58-22	10112-10115	pre	_
58-23	10116-10119	vs.	_
58-24	10120-10124	post	_
58-25	10125-10126	)	_
58-26	10127-10128	,	_
58-27	10129-10132	and	_
58-28	10133-10136	ROI	_
58-29	10137-10139	as	_
58-30	10140-10151	independent	_
58-31	10152-10161	variables	_
58-32	10162-10165	and	_
58-33	10166-10178	drug/alcohol	_
58-34	10179-10185	versus	_
58-35	10186-10193	neutral	_
58-36	10194-10202	contrast	_
58-37	10203-10208	betas	_
58-38	10209-10211	as	_
58-39	10212-10215	the	_
58-40	10216-10225	dependent	_
58-41	10226-10234	variable	_
58-42	10235-10236	.	_

59-1	10237-10247	Subsequent	_
59-2	10248-10249	t	_
59-3	10250-10255	tests	_
59-4	10256-10260	were	_
59-5	10261-10265	then	_
59-6	10266-10270	used	_
59-7	10271-10273	to	_
59-8	10274-10283	determine	_
59-9	10284-10287	the	_
59-10	10288-10294	effect	_
59-11	10295-10297	of	_
59-12	10298-10307	treatment	_
59-13	10308-10310	on	_
59-14	10311-10318	changes	_
59-15	10319-10321	in	_
59-16	10322-10334	drug/alcohol	_
59-17	10335-10345	cue–evoked	_
59-18	10346-10348	FC	_
59-19	10349-10355	across	_
59-20	10356-10363	regions	_
59-21	10364-10365	.	_

60-1	10366-10369	The	_
60-2	10370-10375	focus	_
60-3	10376-10378	on	_
60-4	10379-10381	FC	_
60-5	10382-10390	analysis	_
60-6	10391-10393	in	_
60-7	10394-10397	the	_
60-8	10398-10405	present	_
60-9	10406-10411	study	_
60-10	10412-10413	,	_
60-11	10414-10420	rather	_
60-12	10421-10425	than	_
60-13	10426-10437	traditional	_
60-14	10438-10445	general	_
60-15	10446-10452	linear	_
60-16	10453-10458	model	_
60-17	10459-10467	analysis	_
60-18	10468-10469	,	_
60-19	10470-10473	was	_
60-20	10474-10477	due	_
60-21	10478-10480	to	_
60-22	10481-10484	the	_
60-23	10485-10491	nature	_
60-24	10492-10494	of	_
60-25	10495-10498	TMS	_
60-26	10499-10506	effects	_
60-27	10507-10509	on	_
60-28	10510-10513	the	_
60-29	10514-10519	brain	_
60-30	10520-10521	.	_

61-1	10522-10524	To	_
61-2	10525-10534	influence	_
61-3	10535-10546	subcortical	_
61-4	10547-10552	brain	_
61-5	10553-10560	regions	_
61-6	10561-10562	(	_
61-7	10563-10567	such	_
61-8	10568-10570	as	_
61-9	10571-10574	the	_
61-10	10575-10583	striatum	_
61-11	10584-10585	)	_
61-12	10586-10587	,	_
61-13	10588-10590	we	_
61-14	10591-10598	applied	_
61-15	10599-10602	TMS	_
61-16	10603-10605	to	_
61-17	10606-10614	cortical	_
61-18	10615-10622	targets	_
61-19	10623-10624	(	_
61-20	10625-10629	such	_
61-21	10630-10632	as	_
61-22	10633-10636	the	_
61-23	10637-10642	VMPFC	_
61-24	10643-10644	)	_
61-25	10645-10648	and	_
61-26	10649-10653	took	_
61-27	10654-10663	advantage	_
61-28	10664-10666	of	_
61-29	10667-10670	the	_
61-30	10671-10683	monosynaptic	_
61-31	10684-10694	functional	_
61-32	10695-10706	connections	_
61-33	10707-10714	between	_
61-34	10715-10723	cortical	_
61-35	10724-10727	and	_
61-36	10728-10739	subcortical	_
61-37	10740-10747	regions	_
61-38	10748-10749	.	_

62-1	10750-10752	As	_
62-2	10753-10757	such	_
62-3	10758-10759	,	_
62-4	10760-10762	we	_
62-5	10763-10767	felt	_
62-6	10768-10772	that	_
62-7	10773-10782	measuring	_
62-8	10783-10786	the	_
62-9	10787-10795	efficacy	_
62-10	10796-10798	of	_
62-11	10799-10802	the	_
62-12	10803-10815	cTBS-induced	_
62-13	10816-10823	changes	_
62-14	10824-10826	in	_
62-15	10827-10846	frontostriatolimbic	_
62-16	10847-10855	circuits	_
62-17	10856-10862	should	_
62-18	10863-10865	be	_
62-19	10866-10875	conducted	_
62-20	10876-10878	at	_
62-21	10879-10882	the	_
62-22	10883-10888	level	_
62-23	10889-10891	of	_
62-24	10892-10897	these	_
62-25	10898-10908	functional	_
62-26	10909-10920	connections	_
62-27	10921-10922	.	_

63-1	10923-10935	Relationship	_
63-2	10936-10943	Between	_
63-3	10944-10964	Clinical/Demographic	_
63-4	10965-10974	Variables	_
63-5	10975-10978	and	_
63-6	10979-10981	FC	_
63-7	10982-10989	Changes	_
63-8	10990-10991	.	_

64-1	10992-10994	To	_
64-2	10995-11004	determine	_
64-3	11005-11012	whether	_
64-4	11013-11021	clinical	_
64-5	11022-11025	and	_
64-6	11026-11037	demographic	_
64-7	11038-11047	variables	_
64-8	11048-11058	influenced	_
64-9	11059-11061	or	_
64-10	11062-11071	predicted	_
64-11	11072-11076	cTBS	_
64-12	11077-11086	treatment	_
64-13	11087-11095	outcomes	_
64-14	11096-11097	,	_
64-15	11098-11110	hierarchical	_
64-16	11111-11119	multiple	_
64-17	11120-11126	linear	_
64-18	11127-11138	regressions	_
64-19	11139-11143	were	_
64-20	11144-11153	conducted	_
64-21	11154-11158	with	_
64-22	11159-11167	clinical	_
64-23	11168-11171	and	_
64-24	11172-11183	demographic	_
64-25	11184-11193	variables	_
64-26	11194-11196	of	_
64-27	11197-11205	interest	_
64-28	11206-11208	as	_
64-29	11209-11212	the	_
64-30	11213-11223	predictors	_
64-31	11224-11227	and	_
64-32	11228-11237	covariate	_
64-33	11238-11248	predictors	_
64-34	11249-11252	and	_
64-35	11253-11260	changes	_
64-36	11261-11263	in	_
64-37	11264-11269	VMPFC	_
64-38	11270-11272	FC	_
64-39	11273-11278	after	_
64-40	11279-11283	real	_
64-41	11284-11290	versus	_
64-42	11291-11295	sham	_
64-43	11296-11300	cTBS	_
64-44	11301-11303	as	_
64-45	11304-11307	the	_
64-46	11308-11315	outcome	_
64-47	11316-11324	variable	_
64-48	11325-11326	.	_

65-1	11327-11342	Scalp-to-Cortex	_
65-2	11343-11351	Distance	_
65-3	11352-11363	Measurement	_
65-4	11364-11365	.	_

66-1	11366-11371	Given	_
66-2	11372-11376	that	_
66-3	11377-11380	the	_
66-4	11381-11388	effects	_
66-5	11389-11391	of	_
66-6	11392-11395	TMS	_
66-7	11396-11398	on	_
66-8	11399-11407	cortical	_
66-9	11408-11422	depolarization	_
66-10	11423-11426	are	_
66-11	11427-11439	proportional	_
66-12	11440-11442	to	_
66-13	11443-11446	the	_
66-14	11447-11455	distance	_
66-15	11456-11463	between	_
66-16	11464-11467	the	_
66-17	11468-11473	skull	_
66-18	11474-11477	and	_
66-19	11478-11484	cortex	_
66-20	11485-11486	,	_
66-21	11487-11489	we	_
66-22	11490-11500	calculated	_
66-23	11501-11504	the	_
66-24	11505-11513	distance	_
66-25	11514-11518	from	_
66-26	11519-11522	the	_
66-27	11523-11528	scalp	_
66-28	11529-11531	to	_
66-29	11532-11538	cortex	_
66-30	11539-11541	on	_
66-31	11542-11545	the	_
66-32	11546-11556	transverse	_
66-33	11557-11562	plane	_
66-34	11563-11565	of	_
66-35	11566-11579	magnetization	_
66-36	11580-11588	prepared	_
66-37	11589-11594	rapid	_
66-38	11595-11606	acquisition	_
66-39	11607-11620	gradient-echo	_
66-40	11621-11627	images	_
66-41	11628-11631	for	_
66-42	11632-11636	each	_
66-43	11637-11648	participant	_
66-44	11649-11654	using	_
66-45	11655-11665	BrainRuler	_
66-46	11666-11674	software	_
66-47	11675-11676	,	_
66-48	11677-11678	a	_
66-49	11679-11688	dedicated	_
66-50	11689-11693	tool	_
66-51	11694-11697	for	_
66-52	11698-11713	scalp-to-cortex	_
66-53	11714-11722	distance	_
66-54	11723-11735	measurements	_
66-55	11736-11737	.	_

67-1	11738-11741	The	_
67-2	11742-11749	average	_
67-3	11750-11758	distance	_
67-4	11759-11763	from	_
67-5	11764-11784	participant-specific	_
67-6	11785-11794	placement	_
67-7	11795-11797	of	_
67-8	11798-11801	Fp1	_
67-9	11802-11804	to	_
67-10	11805-11808	the	_
67-11	11809-11815	cortex	_
67-12	11816-11819	was	_
67-13	11820-11824	17.4	_
67-14	11825-11826	±	_
67-15	11827-11830	3.7	_
67-16	11831-11833	mm	_
67-17	11834-11837	for	_
67-18	11838-11845	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
67-19	11846-11851	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
67-20	11852-11855	and	_
67-21	11856-11860	16.4	_
67-22	11861-11862	±	_
67-23	11863-11866	3.2	_
67-24	11867-11869	mm	_
67-25	11870-11873	for	_
67-26	11874-11881	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-27	11882-11887	users	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-28	11888-11889	.	_

68-1	11890-11895	These	_
68-2	11896-11905	distances	_
68-3	11906-11910	were	_
68-4	11911-11923	incorporated	_
68-5	11924-11928	into	_
68-6	11929-11932	the	_
68-7	11933-11941	analyses	_
68-8	11942-11944	as	_
68-9	11945-11955	covariates	_
68-10	11956-11957	.	_

